Skip to main content

Advertisement

SpringerLink
Log in

Rheumatoid Arthritis in the Elderly in the Era of Tight Control

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The principles of treating rheumatoid arthritis (RA) have changed considerably in recent years. Disease-modifying treatment (if possible, methotrexate) should be started as soon as the diagnosis of RA is made. The purpose of treatment is to achieve remission or, alternatively, low disease activity, and patients should be assessed every 1–3 months if they have early RA in order to achieve this aim. The same principles of treatment should apply in the elderly. However, it is more difficult to assess RA activity in the elderly. Overall disease activity and/or pain may be overestimated, as elderly patients may suffer from other diseases. Conversely, the number of joints with synovitis can be underestimated compared with young patients, and regular ultrasound assessment should therefore be considered. Treatment may be more difficult because of concomitant diseases and the increase in drug-related side effects. The role of corticosteroids is still controversial as their short-term symptomatic effects on clinical activity and potential medium-term effect on structural deterioration are counter-balanced by their side effects. Dosages of methotrexate need to be adjusted for creatinine clearance. The anti-tumor necrosis factors (TNFs) appear to be slightly less effective in the elderly. The frequency of adverse effects of anti-TNFs is higher in an elderly population, although the same is seen with comparator disease-modifying treatments. Limited information is available for rituximab and tocilizumab. Uncertainties remain about the management of RA in the elderly as there have been few studies in this population. The safety of the biotherapies therefore still needs to be confirmed, together with the benefit–risk balance of corticosteroid therapy compared with biological therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tutuncu Z, Kavanaugh A. Rheumatic disease in the elderly: rheumatoid arthritis. Rheum Dis Clin North Am. 2007;33:57–70.

    Article  PubMed  Google Scholar 

  2. Soubrier M, Mathieu S, Payet S, Dubost JJ, Ristori JM. Elderly-onset rheumatoid arthritis. Joint Bone Spine. 2010;77:290–6.

    Article  PubMed  Google Scholar 

  3. Pease CT, Haugeberg G, Montague B, et al. Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. Rheumatology (Oxford). 2009;48:123–7.

    Article  CAS  PubMed  Google Scholar 

  4. Villa-Blanco JI, Calvo-Alén J. Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy. Drugs Aging. 2009;26:739–50.

    Article  CAS  PubMed  Google Scholar 

  5. Calvo-Alén J, Corrales A, Sánchez-Andrada S, et al. Outcome of late-onset rheumatoid arthritis. Clin Rheumatol. 2005;24:485–9.

    Article  PubMed  Google Scholar 

  6. Dejaco C, Duftner C, Wipfler-Freissmuth E, et al. Elderly- versus younger-onset rheumatoid arthritis: higher levels of ultrasound-detected inflammation despite comparable clinical disease activity. Arthritis Care Res (Hoboken). 2013;65:304–8.

    Article  Google Scholar 

  7. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–75.

    Article  CAS  PubMed  Google Scholar 

  8. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7.

    Article  PubMed  Google Scholar 

  9. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.

    Article  PubMed  Google Scholar 

  10. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis. 2010;69:638–43.

    Article  PubMed  Google Scholar 

  11. Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford). 2010;49:2154–64.

    Article  Google Scholar 

  12. Sen D, Brasington R. Tight disease control in early RA. Rheum Dis Clin North Am. 2012;38:327–43.

    Article  PubMed  Google Scholar 

  13. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–9.

    Article  PubMed  Google Scholar 

  14. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443–9.

    Article  CAS  PubMed  Google Scholar 

  15. Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis. 2005;64:1294–8.

    Article  CAS  PubMed  Google Scholar 

  16. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis. 2010;69:65–9.

    Article  CAS  PubMed  Google Scholar 

  17. Soubrier M, Lukas C, Sibilia J, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis. 2011;70:611–5.

    Article  CAS  PubMed  Google Scholar 

  18. Felson DT, Smolen JS, Wells G, American College of Rheumatology, European League Against Rheumatism, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573–86.

    Article  PubMed  Google Scholar 

  19. Vermeer M, Kuper HH, van der Bijl AE, et al. The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatology (Oxford). 2012;51:1076–80.

    Article  Google Scholar 

  20. Sokka T, Mäkinen H, Hannonen P, Pincus T. Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis. Rheumatology (Oxford). 2007;46:1020–3.

    Article  CAS  Google Scholar 

  21. Khan NA, Spencer HJ, Abda EA, et al. Patient’s global assessment of disease activity and patient’s assessment of general health for rheumatoid arthritis activity assessment: are they equivalent? Ann Rheum Dis. 2012;71:1942–9.

    Article  PubMed  Google Scholar 

  22. Radovits BJ, Fransen J, van Riel PL, Laan RF. Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis. Ann Rheum Dis. 2008;67:1127–31.

    Article  CAS  PubMed  Google Scholar 

  23. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954–60.

    Article  CAS  PubMed  Google Scholar 

  24. Dahl SL, Samuelson CO, Williams HJ, et al. Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials. Pharmacotherapy. 1990;10:79–84.

    CAS  PubMed  Google Scholar 

  25. Rochon PA, Fortin PR, Dear KB, et al. Reporting of age data in clinical trials of arthritis. Deficiencies and solutions. Arch Intern Med. 1993;153:243–8.

    Article  CAS  PubMed  Google Scholar 

  26. Mallen SR, Essex MN, Zhang R. Gastro-intestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2011;27:1359–66.

    Article  CAS  PubMed  Google Scholar 

  27. Musu M, Finco G, Antonucci R, et al. Acute nephrotoxicity of NSAID from the foetus to the adult. Eur Rev Med Pharmacol Sci. 2011;15:1461–72.

    CAS  PubMed  Google Scholar 

  28. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.

    Article  PubMed  Google Scholar 

  29. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. Epub 31 Aug 2013. doi:10.1016/S0140-6736(13)60900-9.

  30. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098.

    Article  CAS  PubMed  Google Scholar 

  31. Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ. 2013;11(346):f3195. doi:10.1136/bmj.f3195.

    Google Scholar 

  32. Soubrier M, Rosenbaum D, Tatar Z, et al. Vascular effects of nonsteroidal antiinflammatory drugs. Joint Bone Spine. 2013;80:358–62.

    Article  CAS  PubMed  Google Scholar 

  33. Schjerning Olsen AM, Fosbøl EL, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123:2226–35.

    Google Scholar 

  34. Schjerning Olsen AM, Fosbøl EL, et al. Long-term cardiovascular risk of NSAID use according to time passed after first-time myocardial infarction: a Nationwide Cohort Study. Circulation. 2012;126:1955–63.

    Google Scholar 

  35. Wang X, Tian HJ, Yang HK, et al. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastro-intestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol. 2011;23:876–80.

    Article  CAS  PubMed  Google Scholar 

  36. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369(9573):1621–6.

    Article  CAS  PubMed  Google Scholar 

  37. Barkin RL, Beckerman M, Blum SL, Clark FM, Koh EK, Wu DS. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging. 2010;27:775–89.

    Article  CAS  PubMed  Google Scholar 

  38. Bressolle F, Bologna C, Kinowski JM, et al. Effects of moderate renal insufficiency on pharmacokinetics of MTX in rheumatoid arthritis patients. Ann Rheum Dis. 1998;57:110.

    Article  CAS  PubMed  Google Scholar 

  39. Díaz-Borjón A. Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. Drugs Aging. 2009;26(4):273–93.

    Article  PubMed  Google Scholar 

  40. Karie S, Grandjbakhch F, Janus N, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology. 2008;47:350–4.

    Article  CAS  PubMed  Google Scholar 

  41. No authors listed. The effect of age and renal function on the efficacy and toxicity of MTX in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group. J Rheumatol. 1995;22(2):218–23.

    Google Scholar 

  42. Wolfe F, Cathey MA. The effect of age on MTX efficacy and toxicity. J Rheumatol. 1991;18:973–7.

    CAS  PubMed  Google Scholar 

  43. Bologna C, Viu P, Jorgensen C, et al. Effect of age on the efficacy and tolerance of MTX in rheumatoid arthritis. Br J Rheumatol. 1996;35:453–7.

    Article  CAS  PubMed  Google Scholar 

  44. Bernatsky S, Ehrmann Feldman D. Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Quebec, Canada. Drugs Aging. 2008;25:879–84.

    Article  CAS  PubMed  Google Scholar 

  45. Wilkieson CA, Madhok R, Hunter JA, et al. Toleration, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages. Q J Med. 1993;86:501–5.

    Article  CAS  PubMed  Google Scholar 

  46. Alivernini S, Mazzotta D, Zoli A, Ferraccioli G. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment. Drugs Aging. 2009;26:395–402.

    Article  CAS  PubMed  Google Scholar 

  47. Rigaudière F, Ingster-Moati I, Hache JC, et al. Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment. J Fr Ophtalmol. 2004;27:191–9.

    Article  PubMed  Google Scholar 

  48. Bathon JM, Fleischmann RM, Van der Heijde D, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006;33:234–43.

    CAS  PubMed  Google Scholar 

  49. Fleischmann R, Iqbal I. Risk benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging. 2007;24:239–54.

    Article  CAS  PubMed  Google Scholar 

  50. Köller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology (Oxford). 2009;48:1575–80.

    Article  Google Scholar 

  51. Genevay S, Finckh A, Ciurea A, et al. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007;57:679–85.

    Article  PubMed  Google Scholar 

  52. Radovits BJ, Kievit W, Fransen J, et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1470–3.

    Article  CAS  PubMed  Google Scholar 

  53. Filippini M, Bazzani C, Favalli EG, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol. 2010;38:90–6.

    Article  CAS  PubMed  Google Scholar 

  54. Lane MA, McDonald JR, Zeringue AL, et al. TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore). 2011;90:139–45.

    Article  CAS  Google Scholar 

  55. Widdifield J, Bernatsky S. Michael Paterson J, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65:353–61.

    Article  Google Scholar 

  56. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:1754–64.

    Article  CAS  PubMed  Google Scholar 

  57. Galloway JB, Hyrich KL, Mercer LK, BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50:124–31.

    Article  CAS  Google Scholar 

  58. Curtis JR, Xie F, Chen L, et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2012;64:1480–9.

    Article  CAS  Google Scholar 

  59. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414–22.

    Article  PubMed  Google Scholar 

  60. Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 2009;60:3180–9.

    Article  CAS  PubMed  Google Scholar 

  61. Dreyer L, Mellemkjær L, Andersen AR, et al. Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides—a follow-up study from the DANBIO Registry. Ann Rheum Dis. 2013;72:79–82.

    Article  PubMed  Google Scholar 

  62. Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, Solomon DH. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008;156:336–41.

    Article  CAS  PubMed  Google Scholar 

  63. Payet Sarah, Gottenberg JE, Mariette X, et al. Tolerance and efficacy of rituximab in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology Air Registry. Arthritis Rheum. 2012;64(10):2168.

    Google Scholar 

  64. Smolen JS, Martin-Mola E, Rubbert-Roth A, et al. Efficacy and safety of tocilizumab in rheumatoid arthritis in patients above and below 65 years of age with an inadequate response to DMARDs. Ann Rheum Dis. 2008;67(2):338.

    Google Scholar 

  65. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156:329–39.

    Article  PubMed  Google Scholar 

  66. Bijlsma JW. Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology (Oxford). 2012;51(Suppl 4):iv9–13.

    Google Scholar 

  67. Ross DA, Cetas JS. Steroid psychosis: a review for neurosurgeons. J Neurooncol. 2012;109:439–47.

    Article  CAS  PubMed  Google Scholar 

  68. Fel A, Aslangul E, Le Jeunne C. Eye and corticosteroid’s use. Presse Med. 2012;41:414–21.

    Article  PubMed  Google Scholar 

  69. Blackburn D, Hux J, Mamdasni M. Quantification of the risk of corticoid-induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17:717–20.

    Article  PubMed  Google Scholar 

  70. Maricic M. Update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2011;37:415–31.

    Article  PubMed  Google Scholar 

  71. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90:859–65.

    Article  CAS  PubMed  Google Scholar 

  72. Aviña-Zubieta JA, Abrahamowicz M, De Vera MA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford). 2013;52:68–75.

    Article  Google Scholar 

  73. Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case–control study. Ann Rheum Dis. 2011;70:956–60.

    Article  CAS  PubMed  Google Scholar 

  74. Dixon W, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis. Ann Rheum Dis. 2012;71:1128–33.

    Article  CAS  PubMed  Google Scholar 

  75. Tutuncu Z, Reed G, Kremer J, et al. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65:1226–9.

    Article  CAS  PubMed  Google Scholar 

  76. Radovits BJ, Fransen J, Eijsbouts A, van Riel PL, Laan RF. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48:906–10.

    Article  Google Scholar 

  77. Ng B, Chu A, Khan M. A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at veterans affairs medical centers. BMJ Open. 2013;3:e002468.

    Article  PubMed  Google Scholar 

  78. Harrold LR, Peterson D, Beard AJ, Gurwitz JH, Briesacher BA. Time trends in medication use and expenditures in older patients with rheumatoid arthritis. Am J Med. 2012;125:937, e9–15.

    Google Scholar 

Download references

Acknowledgments

M. Soubrier, Z. Tatar, M. Couderc, S. Mathieu, and J.J. Dubost declare no relevant conflicts of interest. No funding has been used to prepare the manuscript.

Author information

Authors and Affiliations

  1. Department of Rheumatology, G. Montpied Hospital, BP 69, 63003, Clermont-Ferrand, France

    Martin Soubrier, Zuzana Tatar, Marion Couderc, Sylvain Mathieu & Jean-Jacques Dubost

Authors
  1. Martin Soubrier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zuzana Tatar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marion Couderc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sylvain Mathieu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-Jacques Dubost
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Soubrier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Soubrier, M., Tatar, Z., Couderc, M. et al. Rheumatoid Arthritis in the Elderly in the Era of Tight Control. Drugs Aging 30, 863–869 (2013). https://doi.org/10.1007/s40266-013-0122-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-013-0122-8

Keywords

Search

Navigation